Pfizer (PFE) Tops Q2 EPS by 21c, Beats on Revenue; Offers FY25 EPS Guidance
Tweet
Share
E-mail
Get Alerts PFE Hot Sheet
Price: $28.05 -1.41%
Revenue Growth %: -4.4%
Financial Fact:
Selling, informational and administrative expenses: 3.56B
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: -4.4%
Financial Fact:
Selling, informational and administrative expenses: 3.56B
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Pfizer (NYSE: PFE) reported Q2 EPS of $0.78, $0.21 better than the analyst estimate of $0.57. Revenue for the quarter came in at $14.7 billion versus the consensus estimate of $13.47 billion.
GUIDANCE:
Pfizer sees FY2025 EPS of $2.90-$3.10, versus the consensus of $3.01.
For earnings history and earnings-related data on Pfizer (PFE) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Activist investor presses Xerox to review financial services arm - Bloomberg
- Truist on Mohawk Industries (MHK): 'Valuation Does Not Reflect Changing Story on Industry Shifts'
- BMO Capital Reiterates Outperform Rating on NVIDIA (NVDA)
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
